Ipilimumab, a cancer immunotherapy, reduced scar formation and promoted tissue regeneration in a mouse model of idiopathic ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

A Dutch study finds that rechallenging advanced melanoma patients with ipilimumab and nivolumab (IPINIVO) can lead to ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...